"In the cisplatin-ineligible cohorts, we showed that high event-free survival and overall survival rates can be achieved at 12 and 36 months in patients treated with neoadjuvant avelumab in combination with cisplatin-based chemotherapy," says Jeremy Blanc, MD.
Gilead reported that a numerical improvement in OS favoring sacituzumab govitecan was observed, though the end point was not reached in the intent-to-treat population.
"Although the Medicare physician fee schedule, which is typically the primary focus of many of our discussions, is what is used to determine physician payment for a service, payment for an ASC is governed by separate rules," write Jonathan Rubenstein, MD, and Mark Painter.
The request comes amid growing concerns about the rule’s implications for businesses and employees nationwide.
Patients with high-risk disease were shown to have a significantly higher mean value of SUVmax compared with patients with low-risk disease (23.5 ± 13.2 vs 10.6 ± 5.4; P < 0.05).
"There’s potentially a role here for patients with small renal masses that may not want to proceed with a minimally invasive laparoscopic or robotic procedure," says Arun Rai, MD, MBA, MSc.
The IND acceptance will initiate the launch of a phase 1 trial to evaluate the safety, tolerability, and preliminary anti-tumor activity of 225Ac-FL-020 in patients with mCRPC.
"This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters, so that more physicians and patients can benefit from this technology," says Brittany Hunt.
The approval is based on findings from the phase 3 CheckMate-901 study.
Regarding patient-reported outcomes, those who underwent URS showed higher urinary symptoms, greater pain intensity, and greater pain interference at 1 week following surgery compared with those who underwent SWL.
“If approved by the FDA, this new product will have a significant impact on prostate cancer patients, physicians, and their caregivers by helping to eliminate the inequity of access to PSMA-PET agents, and increase the ability to accurately diagnose cancer early, reducing the cost of care, and increasing the probability of patients’ survival," says Mike Crosby.
"In [bladder cancer], many women's diagnosis is delayed because their hematuria or microscopic hematuria is blamed on urinary tract infections rather than cancer," says Amy Luckenbaugh, MD.
"A unique aspect of AUA guidelines is the robust methodological review," says Todd M. Morgan, MD.
Glenn T. Werneburg, MD, PhD, discusses 2 abstracts from the 2024 SUFU Winter Meeting.
The predictive models identified the number of previous UTI episodes, prior β-lactam nonsusceptibility, prior fluoroquinolone treatment, Census Bureau region (particularly in the South), and race as key predictors of having a non-susceptible isolate to 3 or more antibiotic classes.
Raveen Syan, MD, highlights 2 sessions that she took part in during the 2024 AUA Annual Meeting in San Antonio, Texas on urodynamics in the context of the VALUE trial and the new wave of percutaneous tibial nerve stimulation devices.
Some Ascension hospitals continue to divert ambulances to other facilities for emergency treatment, but some of the system’s hospitals are accepting all patients.
Among the 3 CD70-positive patients, the ORR was 66.7%, with 2 patients achieving a partial response.
"Since the phase 2 data of the combination therapy of LAE002 (afuresertib) plus LAE001 demonstrated encouraging anti-tumor activity and safety profile in patients with mCRPC, a following phase 3 pivotal trial design has been discussed with the US FDA and the approval for the protocol has been received this month," said Yong Yue, MD, PhD.
The first-in-human study expects to begin dosing patients with DF9001 in combination with pembrolizumab in Q4 of 2024.
"When thinking about living with prostate cancer, this is really a couples' disease, and partners' unmet needs should be part of the conversation," says Stacy Loeb, MD.
Preliminary results from the CUPID study were based on data from 11 evaluable patients with advanced prostate cancer.
“Certainly, there are more and more radioligands coming out not only in prostate cancer, but in other cancers related to urology, and I think that's going to be the next big wave,” says Timothy A. Richardson, MD.
RAG-01 is an saRNA therapy that is delivered via intravesical instillation and is designed to target and activate p21, a tumor suppressor gene.
"We were deeply impressed by Galen's performance in the study, that based on our validation, clearly showed how Ibex can support our clinicians in improving diagnostic quality and efficiency, and as a result we have decided to implement it routinely,” says Junya Fukuoka, MD, PhD.
Yōni.Fit is a soft vaginal insert intended to reduce urine leakage due to SUI without interfering with voluntary urination.
Urologist Alex Shteynshlyuger, MD, and others have argued that insurance companies should compensate physicians and their staff for the time spent compiling patient records for payers to review before authorizing treatments.
"In our professional life, awareness of our bias in seeing patients based on their weight, color, age, literacy level, or social status is evident," writes Gopal H. Badlani, MD.
"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.
"225Ac-PSMA-Trillium is a novel approach, which could provide a new treatment to address this unmet need in mCRPC,” says Fred Saad, MD, FRCS.
